Objective-Bone morphogenetic protein-9 (BMP9)/activin-like kinase-1 and delta-like 4 (DLL4)/Notch promote endothelial quiescence, and we aim to understand mechanistic interactions between the 2 pathways. We identify new targets that contribute to endothelial quiescence and test whether loss of Dll4 +/− in adult vasculature alters BMP signaling. Approach and Results-Human endothelial cells respond synergistically to BMP9 and DLL4 stimulation, showing complete quiescence and induction of HEY1 and HEY2. Canonical BMP9 signaling via activin-like kinase-1-Smad1/5/9 was disrupted by inhibition of Notch signaling, even in the absence of exogenous DLL4. Similarly, DLL4 activity was suppressed when the basal activin-like kinase-1-Smad1/5/9 pathway was inhibited, showing that these pathways are interdependent. BMP9/DLL4 required induction of P27 KIP1 for quiescence, although multiple factors are involved. To understand these mechanisms, we used proteomics data to identify upregulation of thrombospondin-1, which contributes to the quiescence phenotype. To test whether Dll4 regulates BMP/Smad pathways and endothelial cell phenotype in vivo, we characterized the vasculature of Dll4 +/− mice, analyzing endothelial cells in the lung, heart, and aorta. Together with changes in endothelial structure and vascular morphogenesis, we found that loss of Dll4 was associated with a significant upregulation of pSmad1/5/9 signaling in lung endothelial cells. Because steady-state endothelial cell proliferation rates were not different in the Dll4 +/− mice, we propose that the upregulation of pSmad1/5/9 signaling compensates to maintain endothelial cell quiescence in these mice. Conclusions-DLL4/Notch and BMP9/activin-like kinase-1 signaling rely on each other's pathways for full activity.
P
roper function of blood vessels requires an intact endothelial monolayer and quiescent endothelial cells (EC). Multiple cytokines activate endothelial sprouting and proliferation during angiogenesis. However, less is known about the mechanisms that maintain or restore EC quiescence. Two critical pathways are delta-like 4 (DLL4)/Notch and BMP9/activin-like kinase-1 (ALK1), which can display cooperative signal transduction 1,2 and inhibit hypersprouting to maintain appropriate capillary density. 3 The cooperative activity of these pathways has not been studied in quiescence or the re-establishment of endothelial homeostasis.
Recent investigations in developmental vasculogenesis and sprouting angiogenesis have provided new insights into the overlapping mechanisms of DLL4 and BMP9 in ECs. These have shown that endothelial Notch and BMP pathway interactions are a complex interplay between coregulation of target gene levels, interdependence at the signal transduction level, and variations in interactions based on anatomic distribution of vessels. [4] [5] [6] [7] [8] Most is understood about the transcription regulation of these pathways via N1ICD/recombination signal binding protein for immunoglobulin kappa J region (RBPJ) and pSmad1/5 activation, respectively. In addition, the basic helix-loop-helix proteins of the Hey family are targets of both Notch and BMP pathways, providing the potential to further regulate ≤2000 additional mRNAs. 9 The ALK1 pathway was also shown to mediate the activation of Hey1 and Hey2 by serum. 10 However, cooperative mechanisms by which these and other pathways mediate quiescence and homeostasis of the adult endothelium remain to be elucidated.
In this study, we sought to identify new mechanisms by which DLL4/Notch and BMP9/ALK1 cooperate to regulate EC quiescence. We showed that stimulation of primary human aortic ECs (HAEC) independently and cooperatively decreases their proliferation and migration and induces the expression of the target genes HEY1 and HEY2. Using siRNA-mediated knockdown, we demonstrated that suppression of either pathway induces a reversal of the antiproliferative effects of the other. We identify P27 KIP1 and thrombospondin-1 (TSP1) as 2 novel mediators of DLL4/Notch and BMP9/ALK1 cross talk involved in HAEC quiescence. The interdependence of these pathways suggests that modulation of one might affect the other in vivo in ECs. To test this, we studied the vasculature of the Dll4 +/− mouse model on a genetic background that yields viable adults. We show that loss of Dll4 leads to increased EC density, impaired vascular branching morphogenesis, and a compensatory increase in pSmad1/5/9 nuclear localization. These data show that loss of Dll4 in vivo, which affects developmental vascular branching, does lead to sustained changes in BMP signaling that are maintained in the adult endothelium.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

DLL4/Notch and BMP9 Cooperatively Suppress HAEC Proliferation and Induce HEY1 and HEY2
During angiogenesis, DLL4 stimulation of Notch in ECs inhibits the tip cell and promotes the stalk cell phenotype. 11 Similarly, BMP9 inhibits tip cell formation and angiogenic sprouting. 12 Although DLL4 and BMP9 work cooperatively to decrease vascular sprouting and to induce vascular stability, 3 little is known about the molecular mechanisms of this interaction, especially in the re-establishment of quiescence in the postnatal vasculature. To identify cell processes and targets regulated by DLL4 and BMP9, we studied their effects on primary human ECs. HAEC express ALK1 and ALK5 as primary transforming growth factor (TGFβ)/BMP receptor family members and Notch1, Notch2, and Notch4 as potential mediators of DLL4 signals. To assess effect of these ligands on human EC, we stimulated subconfluent HAEC with 20 pmols coated DLL4, 5 ng/mL soluble BMP9, or the combination of both ligands for 24 h. The concentration of BMP9 was chosen by dose response analysis ( Figure IA and IB in the onlineonly Data Supplement) and matched physiological circulating levels. 12 Notable changes were observed in HAEC morphology, most dramatically in the DLL4-treated and combination DLL4+BMP9-treated wells ( Figure 1A ). Control cells were elongated, typical of proliferating HAEC, whereas ligand stimulation led to a cobblestone-like morphology, often associated with differentiated, confluent endothelial monolayers.
To assess effects of the ligands on proliferation, we incubated cells with 10 μg/mL 5-bromo-2′-deoxyuridine treatment during the final 6 h of growth. 5-Bromo-2′-deoxyuridine incorporation was quantified ( Figure 1B) . Compared with control, there was a dramatic decrease in proliferation after 24-h stimulation with either DLL4 or BMP9 and additive inhibition with combined ligands. The suppression of proliferation was observed as early as 12 h of ligand treatment and further suppressed by 24 h ( Figure IC in the online-only Data Supplement). The effect of the ligands was reversible because removing cells from ligand exposure re-established normal proliferation ( Figure ID in the online-only Data Supplement).
HEY1 and HEY2 basic helix-loop-helix transcriptional repressors are well-established targets of both Notch and BMP signaling. Quantitative reverse transcriptase polymerase chain reaction analysis of HEY1 and HEY2 transcripts demonstrated induction of both genes and a cooperative induction with combined ligand treatment ( Figure 1C and 1D ).To validate BMP9 activity, we treated HAEC with BMP9 and analyzed cells by immunofluorescence and clearly observed pSmad1/5 (pS463/465) translocation to the nucleus ( Figure 1E ). We also immunoblotted lysates from 24-h ligand-stimulated cells and observed that pSmad1/5 is highly increased by BMP9, decreased by DLL4, and significantly higher than baseline in the combined stimulation ( Figure 1F and 1G) . We examined the protein levels of growth arrest-specific gene 1 because it is associated with G0 cell cycle arrest, but found no changes after DLL4 or BMP9 treatment ( Figure IE in the online-only Data Supplement). To rule out that the decrease in proliferation was a secondary effect of cellular senescence, we analyzed levels of senescence-associated β-galactosidase activity, which was virtually undetected under control or ligand-treated conditions ( Figure IF in the online-only Data Supplement). Finally, to determine whether ligand stimulation affects endothelial activation, we first treated HAEC with lipopolysaccharide and found that intercellular adhesion molecule-1 was the most robustly induced inflammatory mediator ( Figure IG in the online-only Data Supplement). Ligand-stimulated HAEC demonstrated a more potent induction of intercellular adhesion molecule-1 on activation with bacterial lipopolysaccharide and polyinosinic:polycytidylic acid, a mimic for viral infection ( Figure IH in the online-only Data Supplement). Thus, although DLL4 and BMP9 induce a quiescent state in ECs, they increase sensitivity to strong activation cues.
Cooperative Proliferation Effects of DLL4/ Notch and BMP9 Are Reversed by Knocking Down Components of Each Pathway
We next sought to clarify specific signaling mechanism required for interaction of DLL4/Notch and the BMP9/ALK1 pathways. We used siRNA knockdown to target key components of each pathway. First, to identify the Notch responsible for DLL4-mediated cellular quiescence, we knocked down the Notch1 (siN1), Notch2 (siN2), and Notch4 (siN4) receptors, which resulted in 92%, 86%, and 78% reduction of each receptor, respectively, relative to a nontargeting siRNA control (Figure 2A-2C) . These are the primary Notch proteins expressed in human ECs, with Notch3 present at low levels ( Figure IIIA in the online-only Data Supplement). SiRNAtargeted cells were stimulated with ligands, and proliferation was measured (Figure 2A-2C ). We found that suppression of Notch1 rendered the cells insensitive to the quiescence signal of DLL4 and also BMP9 (Figure 2A ). However, loss of Notch2 or Notch4 did not affect the sensitivity of the cells to either ligand ( Figure 2B and 2C). The loss of Notch1 also significantly suppressed the induction of HEY1 in all ligand conditions ( Figure 2D ). Using antibodies specific to the cleaved, activated forms of Notch1, Notch2, and Notch4 in immunoblot, we confirmed that only Notch1 was activated by DLL4 in HAEC ( Figure 2E ). BMP9 did not increase activated forms of any Notch receptor, even in the presence of DLL4 ( Figure 2E and 2F). These results clearly identified Notch1 as the primary DLL4 receptor and led to the unexpected finding that ECs have decreased sensitivity to BMP9-mediated regulation of cell growth in the absence of Notch1. Another key component of Notch signaling is the transcriptional coactivator RBPJ. A 90% knockdown of RBPJ (siRBPJ; Figure 2G ) led to the partial reversion of the proliferation effects of DLL4, BMP9, and the combination. These data indicate a requirement for Notch1/RBPJ signaling as a component of BMP9 initiation of quiescence. The primary receptor for BMP9 on ECs is ALK1, which phosphorylates Smad1/5/9 proteins, leading to interaction with Smad4 and activation of target genes. We suppressed ALK1 by siRNA (siALK1, 83% suppression; Figure 2H ), and as expected, knockdown of ALK1 led to insensitivity to BMP9 ( Figure 2H ). Suppression of ALK1 was only partially able to reverse the inhibitory effects of DLL4 on cell proliferation. When we knocked down the Smad1/5/9 proteins by 81% (siSM1/5; Figure 2I ), effects of BMP9 were completely abolished. Loss of Smad1/5/9 also partially reversed the growth Figure 1 . Delta-like 4 (DLL4)/Notch and bone morphogenetic protein-9 (BMP9) cooperatively suppress endothelial cell proliferation and induce HEY genes. A, Primary human aortic endothelial cells (HAEC) were stimulated with ligand as described for 24 h. Scale bar=50 μm. B, After 18-h treatment, cells were given 10 μg/mL 5-bromo-2′-deoxyuridine (BrdU) for the last 6 h of growth. Cells were fixed at 24 h and processed for immunostaining with anti-BrdU. The percentage of BrdU-positive cells was calculated (n=10 per condition). Graphed are means±SD. C and D, Cells under the same experimental conditions were grown for 24 h, and total RNA was collected for quantitative polymerase chain reaction (qPCR). Primers were used to amplify HEY1 and HEY2 transcripts normalized to PPIA (cyclophilin). Graphed are fold change means compared with control±SD. E, HAEC were synchronized by serum starvation for 8 h, treated with vehicle or BMP9 for an additional 16 h, then fixed and stained for phospho-Smad1/5 (pS463/465). Scale bar=50 μm. F, HAEC were treated with vehicle or ligands for 24 h, and whole cell lysates were immunoblotted for phospho-Smad1/5 (pSmad1/5) and total Smad1/5 (total Smad1/5). pSmad1/5 present as a doublet, and the bands were quantified separately. G, Quantified immunoblot bands were normalized to β-actin and represented as a percentage of vehicle. * indicates a statistical significance with P<0.05. suppression effects of DLL4. Thus, although Notch1 signaling is critical for propagation of the BMP9 signal, interruption of the BMP9 pathway diminished, but did not eliminate, DLL4/Notch1 signaling.
ALK1 also signals in a Smad-independent manner, through pathways including TGF-β-associated kinase 1 (TAK1). To determine whether TAK1 mediates the effects of BMP9 or DLL4, we treated cells with a TAK1 inhibitor. Suppression of TAK1 activity had a global effect of suppression of proliferation ( Figure IIA in the online-only Data Supplement), suggesting that basal levels of TAK1 support transit through the cell cycle. These data point to pSmad signaling as the primary pathway mediating specific BMP9/ALK1 signals for endothelial quiescence.
Multiple Cell Cycle-Related Proteins Are
Affected by DLL4 and BMP9 Stimulation, and P27
KIP1 Is a Major Mediator of Quiescence
To further understand the molecular regulation of endothelial quiescence, we analyzed cell cycle-associated proteins following stimulation with DLL4, BMP9, or both. Immunoblots (siN1), Notch2 (siN2), or Notch4 (siN4) was validated by immunoblot (8%, 14%, and 22% of NT, respectively). HAEC were treated with ligand as indicated, and proliferation measured by 5-bromo-2′-deoxyuridine (BrdU) incorporation. D, HAEC targeted with siN1 or NT siRNA were treated with ligands, and HEY1 mRNA quantified by quantitative polymerase chain reaction (qPCR). E, HAEC were treated with vehicle or ligands for 24 h, and whole cell lysates were immunoblotted for cleaved, activated forms of Notch1 (V1744), Notch2 (D1733/A1734), or Notch4 (V1432) and quantified in comparison to β-actin (F). G, siRNA was used to suppress RBPJ (siRBPJ), and cell lysates were immunoblotted to confirm loss of protein (10% of NT). Proliferation was measured using BrdU incorporation. Similar knockdown experiments targeted ALK1 (H, siALK1, 17% of NT) or Smad1/5/9 (I, siSmad1/5, 19% of NT). Graphed are means±SD. * signifies statistical significance with P<0.05. † signifies statistically significant reversal of effects (P<0.05). December 2015
were run using whole cell lysates of vehicle (Veh) or ligandstimulated HAEC (Figure 3A and 3B; Table IA and IB in the online-only Data Supplement). Several proteins were altered after ligand stimulation ( Figure 3A ). Despite the potent decrease in proliferation, several cell cycle inhibitors were decreased, including P18
INK4C
, P19
INK4D
, and P21
CIP1
, the latter being a transcriptional target of p53, which also decreased as a result of ligand stimulation. Potentially contributing to the decreased proliferation, we observed decreases in cyclinD1 (by both DLL4 and BMP9) and cyclinD3 (by DLL4 only). The cyclin-dependent kinases (CDK) typically associated with the D-type cyclins also changed, albeit differentially, with CDK4 decreasing and CDK6 increasing on stimulation with the ligands. To corroborate our 5-bromo-2′-deoxyuridine measurements of proliferation, we evaluated levels of the Ki-67 marker of proliferation. Ki-67 was significantly decreased after stimulation with DLL4 and BMP9, and levels were correlated with levels of proliferation. Proteins with negligible change after ligand stimulation were the P14 ARF , P15
INK4B
, and P16
INK4A cell cycle inhibitors, cyclinE1 and E2, and CDK2 ( Figure IIB and IIC in the online-only Data Supplement).
The most potently upregulated cell cycle inhibitor observed was P27 KIP1 (Figure 3A-3C; Table IA -IC in the online-only Data Supplement), whose induction correlated with decreased proliferation for each ligand, especially the combined ligand stimulation. Potential contributors to elevated P27 KIP1 were decreased levels of the S-phase kinase associated protein-2 (SKP2) E3 ubiquitin ligase, which targets P27 KIP1 for proteosomal degradation, and increased phosphorylation of the serine-10 residue of P27 KIP1 , which enhances the half-life and stability of the protein 13 ( Figure 3B ). In addition, P27
KIP1 phosphorylation on threonine-157 is associated with its cytoplasmic retention, which is associated with its functional inactivation.
14,15 DLL4 and BMP9 reduced the levels of pP27 KIP1 (T157), which is expected to increase nuclear localization ( Figure 3B ), consistent with growth suppression. Indeed, immunofluorescent staining of ligand-stimulated cells revealed increased nuclear P27 KIP1 intensity, inversely correlating to the trend of decreasing proliferation ( Figure 3C ). We observed similarly increased nuclear P27 KIP1 immunofluorescence intensities and corresponding decreases in proliferation when we stimulated a variety of other primary human KIP1 mediates the quiescence signal of delta-like 4 (DLL4) and bone morphogenetic protein-9 (BMP9). Primary human aortic endothelial cells (HAEC) were treated with ligands as indicated. A and B, Cell lysates were collected after 24 h for immunoblot using antibodies against cell cycle regulatory proteins. Quantification of the immunoblot bands in panels A, B, and E are given in Table I in the online-only Data Supplement. C, Cells stimulated under the same conditions were fixed after 24 h and immunostained for P27 KIP1 (scale bar=100 μm), and nuclear fluorescence intensity was quantified. Graphed are means relative to vehicle±SD, N≥5 fields per condition. D, P27 KIP1 was targeted using siRNA (siP27) compared with nontargeting (NT) siRNA, and protein levels detected by immunoblot. E, Proliferation after knockdown of P27 KIP1 was measured by 5-bromo-2′-deoxyuridine (BrdU) incorporation. F, Cells were transduced with adenoviral vectors with control LacZ (adLacZ) or an expression construct for S-phase kinase associated protein-2 (SKP2; adSKP2). Cell lysates were immunoblotted, validating the overexpression of SKP2 (2232% of control) and consequent downregulation of its target P27 KIP1 (63% of control). G, Cells transduced with control AdLacZ or AdSKP2 were stimulated with ligands or vehicle control and proliferation measured by BrdU. SKP2 overexpression reversed the proliferation effects of the ligands (G) and significantly decreased the ligand-mediated nuclear intensity of P27 KIP1 (H). Graphed are means±SD. * signifies statistical significance of P<0.05. † signifies statistically significant reversal of effects (P<0.05).
EC types with DLL4 and BMP9 (Figure IIIB-IIIH in the online-only Data Supplement). We used siRNA knockdown to further investigate the contribution of P27 KIP1 to ligandinduced changes in proliferation and were able to suppress P27 KIP1 by ≈92% ( Figure 3D ; Table IC in the online-only Data Supplement). Without P27 KIP1 , the effects of DLL4 and combined DLL4 and BMP9 were blunted, and BMP9 was unable to suppress proliferation ( Figure 3E ).
To determine whether the ligand-mediated suppression of SKP2 was also contributing to the upregulation of P27 KIP1 , we used an adenoviral construct to overexpress the SKP2 protein (AdSKP2). We validated the overexpression of SKP2 and the corresponding decrease in endogenous baseline expression of P27 KIP1 by immunblot ( Figure 3F ). AdSKP2 significantly rescued the proliferation of the cells from ligand-mediated suppression ( Figure 3G) , and the nuclear P27 KIP1 intensities were correspondingly decreased as well ( Figure 3H ).
Endothelial cells are sensitive to cytokine stimulation, and Notch signaling influences vascular endothelial growth factor (VEGF) activity by regulating VEGF receptors. [16] [17] [18] To test the possibility that loss of sensitivity to growth factors was responsible for the quiescence, we analyzed levels of growth factor receptors. As expected, VEGFR2 was decreased by DLL4. In addition, neuropilin1 was suppressed by treatment with DLL4 and BMP9. 19 Moreover, EGFR1 (epidermal growth factor receptor-1) and the FGF (fibroblast growth factor) receptors were also suppressed by ligand treatment, and VEGFR1 was induced ( Figure IVA and IVB in the online-only Data Supplement). Because lower yet significant levels of receptors were still present, we tested whether the quiescence could be overcome by cytokine supplementation. However, despite high levels of additional growth factors, DLL4 and BMP9 still fully invoked the quiescent phenotype under serum-free conditions ( Figure IVC 
DLL4 and BMP9 Regulate Extracellular Matrix Proteins and TGF-β
A quantitative mass spectrometric proteomic screen was performed as previously described 20 to identify changes in protein profiles during DLL4-and BMP-induced EC quiescence. Interestingly, several extracellular matrix (ECM) proteins were identified as induced by ligand stimulation ( Figure 4A ). Noteworthy among them, TSP1 is a potent inhibitor of endothelial proliferation. 21 Fibronectin and collagen type IV (COL IV) were also significantly increased. To validate the mass spectrometry data, immunoblots and immunofluorescence assays were performed on vehicle and ligand-stimulated cells. Both confirmed increased ECM in ligand-stimulated cells ( Figure 4B-4E) , as well as verified proteins that were unchanged by ligand stimulation (β-catenin and PECAM). Although the majority of the increased fibronectin was localized intracellularly, TSP1 accumulated in fibrillar networks on the surface of cells, and COL IV was secreted and deposited in a dense network between cells ( Figure 4E ). To determine the contribution of each ECM component to induction of quiescence, 5-bromo-2′-deoxyuridine proliferation assays were performed with cells plated on ECM-coated plates (60 pmols/ well, Figure 5A ). Among the individual ECM proteins, only TSP1 decreased proliferation, whereas COL IV and fibronectin did not significantly change proliferation. However, the combination of COL IV, fibronectin, and TSP1 together (60 pmols/ECM/well) had a stronger quiescence effect than TSP1 alone, implying that either the suppressive effects of TSP1 are amplified when combined with fibronectin and COL IV or a different antiproliferative signal results as cells contact all 3 ECM components simultaneously. Stimulation of cells with TSP1 did not significantly affect P27 KIP1 overall expression levels or nuclear intensity, nor did TSP1 independently increase the baseline activation of Notch1 ( Figure 5B ). To determine whether increased TSP1 contributed to DLL4-and BMP9-induced quiescence, we used siRNA, which suppressed TSP1 protein by an average 82% ( Figure 5C and 5D ). There was a small but statistically significant rescue of proliferation when TSP1 was decreased in the presence of ligand ( Figure 5E ). Two of the major receptors for TSP1 implicated in its effects on proliferation are CD36 and CD47. We probed for these receptors by immunoblot and found them differentially regulated on ligand stimulation, with CD36 levels decreased and CD47 levels increased ( Figure 5F and 5G). Although the changes in these receptors could be a direct result of regulation by the ligands, it could also be that the receptors are internalized and degraded on binding TSP1. 22, 23 There is some overlap in the activation of Smads with BMP family members and other TGFβ ligands, and TGFβ1 can also suppress EC proliferation and regulate ECM production. Thus, we tested whether DLL4 regulated the production of TGFβ1. We found that both DLL4 and BMP9 increased TGFβ1 in whole cell lysates, as well as the conditioned medium ( Figure 5F ). In addition, TGFβ1 also cooperated with DLL4 in suppressing cell proliferation ( Figure 5G ). December 2015
Loss of Dll4 in Dll4 +/− Mice Alters BMP Signaling In Vivo in Endothelium
Our in vitro studies found that DLL4 and BMP9 signaling in ECs is interdependent and requires the other pathway for full activity. Developmental angiogenesis is regulated by these pathways, and our studies in human cells show important functions in quiescence of adult ECs. Our data lead to the prediction that loss of Dll4 signaling in the mouse would modify BMP signaling in ECs. To test this, we used the previously developed Dll4 targeted mutation, 24 which has been used to show a critical role for Dll4 in embryonic development. On a C57BL/6J background, this mutation caused haploinsufficient lethality with vascular remodeling defects. However, on a congenic FVB/NJ background, some To determine the levels of Dll4 protein in the Dll4 +/− mice, we collected tissue lysates from mouse aortae ( Figure 6A ). We consistently saw decreased Dll4 protein compared with wildtype, with vessels from Dll4 +/− mice containing about one third of normal levels. Based on our in vitro results, we predicted that decreased Dll4 might lead to increased cell proliferation that would be reflected in the mature adult vessel. Thus, we performed both en face staining of aortic segments to quantify EC density and also analyzed cross sections for vessel morphometry. We found that, indeed, the density of ECs per area in the aorta was significantly increased in the Dll4 +/− mice ( Figure 6B ), and this corresponded to an increase in vessel lumen size ( Figure 6C ). The increased density of ECs in the aorta was consistent in different ages and genders of mice, ranging from 3-month-old to 9-month-old individuals ( Figure VIA in the online-only Data Supplement). Although normal adult vascular smooth muscle cells do not express significant levels of Dll4 protein, ECs regulate medial smooth muscle cells in a paracrine manner. Thus, we analyzed medial thickness and smooth muscle cell density in aortae. We found increased medial wall thickness in the Dll4 +/− mice ( Figure 6D ) without an increase in smooth muscle cell numbers, leading to a decreased density of cells/area ( Figure 6E ). We also analyzed the vasculature in the hearts of wild-type versus Dll4 +/− mice. After staining to detect ECs, we measured and counted blood vessels. We grouped vessels based on size from 10 to 50 μm to >600 μm. We did not find any significant differences in the number of vessels per area when comparing hearts from wild-type versus During the course of histological analysis of tissues, we noted that some of the lungs from Dll4 +/− mice had areas of hemorrhage ( Figure 6F ), similar to phenotypes of some components of the Bmp9/Alk1 pathway, including loss of function of the coreceptor endoglin 25 and loss of function Alk1. 26 Because Dll4/Notch regulates branching morphogenesis, we visualized the lung vasculature by Microfil perfusion followed by microCT analysis. Although there was some variability in perfusion patterns, several Dll4 +/− lungs showed significant deviation from the highly structured, organized patterning of wild-type lung vasculature ( Figure 6G ; Video in the online-only Data Supplement). In addition to developmental branching, other aspects such as EC growth or pruning patterns could contribute to this phenotype during the establishment of the lung vasculature. To test for changes in EC proliferation, we stained lung sections to detect the proliferation antigen Ki-67 and did comprehensive analysis of labeled ECs within the lung vasculature. In these adult lungs, there was no significant difference in the proliferation rate of lung endothelium ( Figure 6H ). To assess BMP/ALK signaling in lung ECs, we immunostained and analyzed nuclear pSmad1/5 protein. We found a highly significant increase in pSmad1/5 nuclear staining in the lung vasculature of the Dll4 +/− mice ( Figure 6I ), suggesting compensatory signaling with the decrease in Dll4.
Discussion
The Notch and TGFβ/BMP signaling pathways are currently being targeted for clinical therapies related to angiogenesis. Inhibitors of ALK1 include an extracellular ALK1 domain fused to Fc that binds BMP9 and BMP10 and acts as a competitive inhibitor and a humanized mAb against ALK1 (reviewed in Bhatt and Atkins 27 ). Likewise, inhibition of DLL4/Notch1 has been proposed as a method to inhibit tumor angiogenesis by increasing sprouting in angiogenic vessels, KIP1 and contributes to the quiescence phenotype induced by delta-like 4 (DLL4) and bone morphogenetic protein-9 (BMP9). A, Extracellular matrix proteins were used to coat dishes at 60 pmoles/well, and primary human aortic cells (HAEC) were plated on top for 24 h, followed by assessment of proliferation by 5-bromo-2′-deoxyuridine (BrdU) incorporation (black bars). Immunofluorescence staining was used to measure nuclear P27 KIP1 under different conditions (gray bars). Graphed are means±SD. B, Cell lysates were collected 24 h after plating on TSP1 for immunoblot to quantify cleaved Notch1 and P27 KIP1 (106% and 93% of vehicle, respectively). C, Immunoblot was used to show efficacy of TSP1 knockdown using targeted siRNA (siTSP1) relative to nontargeting control (NT). Immunoblot results were quantified as a percentage of siTSP1 relative to NT. D, siTSP1 cells had significantly reduced sensitivity to the quiescence signals mediated by DLL4 and BMP9. Graphed are means±SD. E, Cell lysates from ligand-treated cells were analyzed by immunoblot for the TSP1 receptors CD36 and CD47. Quantified immunoblot bands are represented in graphical form as a percentage of vehicle. F, HAECs were stimulated with ligands in serum-free and growth factor-free media for 24 h. Conditioned media (CM) and whole cell lysates (WCL) were collected and immunoblotted for transforming growth factor-β (TGFβ). leading to reduced perfusion and thus hypoxia (reviewed in Yan 28 ). However, challenges include unwanted side effects, such as pathological activation of endothelium, leading to vascular tumors and disrupted organ homeostasis 29 and telangiectasias. 30 Our results in human ECs provide mechanistic insight into how blocking these pathways would negatively affect vascular quiescence and homeostasis.
Cooperative activity between Notch and TGFβ/BMP signaling is not unprecedented. Signals from multiple BMP family members lead to interaction of Notch1 intracellular domain and the Smad proteins, potentiating their transcriptional activity on shared target genes. 1, 31, 32 In embryonic zebrafish, Notch and ALK1 signaling coregulated development of certain vessels, but had differential regulation of certain target genes and cranial vessels and distinct phenotypes of arteriovenous malformations. 6 In mouse ECs, cooperative activity of BMP6 was shown with Notch signaling on Hey transcription factors. 2 Although little is known about signal interactions between DLL4/Notch and BMP9/ALK1 cascades, their high significance in angiogenesis and vascular pathology have been elegantly shown in mouse vascular developmental and disease models and venous-derived ECs.
3 Suppression of +/− relative to the average of the WT bands. B, Thoracic aortae were fixed, stained with Hoechst nuclear dye, and endothelial density measured by immunofluorescent imaging. Graphed are means±SEM. C-E, Transverse sections of paraffin-embedded thoracic aortas of littermates were H&E stained, and lumen circumference (C), aorta wall thickness (D), and smooth muscle cell density (E) were measured. N=9 mice/group. Graphed are means±SEM. F, Sections of paraffin-embedded lungs from littermates were H&E-stained, revealing extensive red blood cell infiltration of alveolar spaces. Scale bar=50 μm. G, Lung vasculature was perfused with radiopaque silicone rubber (Microfil) and imaged by microcomputed tomography. Irregular vascular branching patterns can be observed in Dll4 +/− lung. Scale bar=1 mm. H, Sections of paraffinembedded lungs were immunohistochemically stained for the ki67 proliferation marker, and endothelial cells positive for the marker were counted and quantified relative to total vessel lumen circumference. Graphed are means±SEM. N=7 mice/group. I, Sections of paraffinembedded lungs were immunohistochemically stained for phospho-Smad1/5, and staining intensity of endothelial nuclei was measured. DLL4, BMP9, or ALK1 signaling enhanced tube formation, thus coordinately regulating angiogenesis. Similarly, Dll4 deficiency in Dll4 +/− mice led to increased collateral network formation after ischemia; however, tissue perfusion was not increased, suggesting the formation of poor quality vasculature. 33 In addition to ECs, Dll4 is also involved in other cells that regulate cardiovascular diseases, including inflammatory cells. Aikawa et al showed that Dll4 regulates macrophage activity, leading to changes in atherosclerosis and metabolic dysfunction. 34 During remodeling, Dll4 plays an important role in vascular maturation, and our studies would suggest that establishment of cellular quiescence is a vital part of this maturation.
Our study is the first to focus on DLL4 and BMP9 signaling in human arterial ECs to study their combined effects on cellular quiescence. One important finding was related to the Notch protein that interacts with DLL4. Our findings show that Notch1 specifically mediates the DLL4-induced quiescence signal. Interestingly, Notch1 was recently implicated in EC senescence, with activation of Notch1 by Jagged1 proposed to increase cellular lifespan, corresponding to suppression of p53, p21 cip1 , and p16. 35 In our studies, we did see, separately, DLL4 and BMP9 suppression of p21 and p53, but this suppression was not associated with changes in cellular senescence. Despite low levels of Notch3 in all of our ECs, it may also have been activated by DLL4, but we did not conduct those studies because of a lack of cleaved/activated Notch3 antibody. 36, 37 Recent investigations have also demonstrated the antagonistic interactions of Jagged1 with DLL4 for proper angiogenesis and mural cell recruitment for vessel maturation. 7, 38 It was shown that DLL4 activation of Notch1 increased the levels of Jagged1, which activated Notch4 to negatively regulate DLL4, but also increased mural cell coverage of nascent vessels. This negative feedback feature of vessel maturation may also be coregulated by BMP9 signaling because ALK1 also maintains Jagged1 expression levels. 39 Our studies also show that BMP9/ALK1 suppression of proliferation occurs primarily via Smad signaling. Suppression of Smad expression by targeted siRNA abrogates the BMP9 suppressive effect and even leads to enhanced proliferation. This observation may be because BMP9/ ALK1 activates Smad-independent pathways, such as TAK1. Although predominant Smad signaling in ECs overall inhibits proliferation, the downstream targets of pTAK1 (MEK1/2, MEK4/7, MEK3/6, IKKα/β) clearly activate proliferation. In fact, use of a TAK1 inhibitor completely suppressed EC proliferation, supporting its endogenous role to promote cell cycle progression. This view is supported by other studies of siRNA-mediated suppression of TAK1 in ECs, which led to suppressed proliferation, migration, and tube formation. 40 Thus, we propose that primary BMP9 signaling in human ECs is mediated via Smad activation to promote the quiescence phenotype, and when Smad is lacking, signaling via alternative pathways, such as TAK1, may predominate. Although not addressed in our study, another ligand that activates ALK1 and the Smad pathway is BMP10. In zebrafish embryos, Bmp10 was shown to activate Smad1/5/9 to promote EC quiescence in response to blood flow, whereas Bmp9 was not involved for this effect. 41 In humans, by inference from mouse genetic phenotypes, it is expected that there may be some overlapping and some unique functions between BMP9 and BMP10, possibly depending on the tissue. 42, 43 Our novel finding that DLL4-and BMP9-induced quiescence is associated with accumulation of specific ECM proteins has implications for cytokine signaling and angiogenesis. Perhaps most well characterized are the matrix effects on VEGF signaling, which in the presence of matrix proteins causes interaction of the VEGFR and integrins and modification of signaling. 44 Vascular-expressed matrix proteins, such as laminin 10, signal through integrins to regulate the expression of DLL4, 45 and we show a reciprocal regulation of DLL4 toward specifically TSP1, fibronectin, and COL IV. TSP1 is a well-known inhibitor of endothelial proliferation, 46 but its regulation by Notch signaling has not been previously shown. TSP1 contributes to the mature, differentiated phenotype of adult ECs, 47 and this is consistent with its induction by BMP9 and DLL4, which promote vascular quiescence. Although proliferation was suppressed, we did not observe any changes in P27 KIP1 or activated Notch1 on stimulation of ECs with TSP1, which indicates that TSP1 contribution to vascular quiescence is likely via inhibition of growth factor signaling. [48] [49] [50] [51] Although TSP-1 was the only one of these ECM proteins that was sufficient to decrease proliferation, the change in overall cellular microenvironment is expected to impact growth factor availability, cell motility, and cytokine signaling. The finding that TSP1 is induced by BMP9 and DLL4 may potentially impact the pursuit of anti-angiogenic molecules because combined therapeutics can provide multimodal strategies. [52] [53] [54] Overall, our studies using human ECs suggest a model where DLL4 and BMP9 pathways activate multiple regulatory nodes to maintain a quiescent phenotype ( Figure VII in the onlineonly Data Supplement).
Based on our in vitro studies, we used a mouse model to further understand whether modulating Dll4 in vivo would lead to changes in BMP9 signaling and endothelial phenotype. Previously, haploinsufficiency of Dll4 +/− in the mouse was shown to be embryonic lethal, with development halting at midgestation because of severe defects in vascular remodeling. 24 However, we found heterozygosity for this Dll4 mutant allele was better tolerated on the FVB/NJ background, where we could generate some Dll4 +/− mice with decreased protein levels. Although EC proliferation was not different compared with wild-type mice in the adult, there was evidence of development changes in EC growth and morphogenesis. The aorta of Dll4 +/− adult mice had an elevated density of ECs, suggestive of an increased proliferation rate at some point during development or vascular growth. Although no changes in steady-state proliferation were noted in adult ECs, vessels in the lung had dramatically elevated nuclear pSmad1/5. Because we found that BMP9 quiescence signals depend on pSmad1/5, elevated pSmad signaling may be a compensatory response to decreased Dll4 that maintains endothelial homeostasis. The complex changes in lung vascular morphogenesis may be a result of developmental changes in EC proliferation, branching morphogenesis, or pruning. We found evidence in some Dll4 +/− lungs for hemorrhage, which has also been described for lungs in the endoglin heterozygous mice 25 and the endothelial-specific Alk1 knockout mouse. 26 This in vivo phenocopy of these genetic mutants again supports the cooperative nature of these signaling pathways. Current therapies incorporating Notch or BMP targets to prevent or augment various vascular processes like angiogenesis (eg, wound healing, cancer) or treat pathologies, such as hereditary hemorrhagic telangiectasia, neointimal hyperplasia, or pulmonary hypertension, can benefit from the cooperative nature of the 2 pathways because they are provided a larger arsenal of targets and more nuanced strategies.
